Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sublingual immunotherapy peanut extract + glucopyranosyl lipid a
- Development stage
- Preclinical
- Lead developer
- Sanofi
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Small Molecules
- Administration
- Sublingual
01
Overview
This is a **combination immunotherapy drug** consisting of peanut allergen extract delivered by sublingual immunotherapy (SLIT) and the adjuvant **glucopyranosyl lipid A (GLA)**, a synthetic Toll-like receptor 4 (TLR4) agonist. The combination aims to desensitize patients with peanut allergy and potentially enhance immune modulation by shifting responses from a pathological Th2 allergy profile to a protective Th1 profile and increasing regulatory T cell activity. GLA acts as an immunostimulatory adjuvant, enhancing antigen presentation and promoting Th1-biased immune responses, reducing allergic inflammation and allergy-associated cytokines such as IL-5, and increasing IFN-γ. This combination leverages both the established efficacy of SLIT for allergic desensitization and the immune-boosting effects of a TLR4 agonist. This drug is mainly in preclinical or early clinical investigation stages for **peanut allergy** and potentially other food allergies, but specific clinical trials in humans using the sublingual route and combining peanut extract with GLA are not yet published as of current data[1][2].
- Other names
- peanut SLIT + GLApeanut sublingual immunotherapy + GLA
02
Targets
TLR4 (Toll-like receptor 4)Ara h 6
Beyond the preview
Go deeper on sublingual immunotherapy peanut extract + glucopyranosyl lipid a.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sublingual immunotherapy peanut extract + glucopyranosyl lipid a.